CuriRx Launches the Advanced Bioprocessing and Analytical Center to Support Biotherapeutic Drug Developers
WILMINGTON, Mass., Jan. 26, 2022 /PRNewswire/ — CuriRx, Inc., a leading contract research, development and manufacturing organization (CRDMO), announced today the launch of the Advanced Bioprocessing and Analytical Center. Led by CuriRx’s team of industry experts and state-of-the-art bioprocessing laboratories combined with the CuriLytics® Platform’s high-resolution analytical instrumentation, the Advanced Bioprocessing and Analytical Center provides end-to-end support to developers of biotherapeutics. Modern biopharmaceutical drugs, such as recombinant proteins, monoclonal antibodies (mAb), bispecific antibodies, vaccines, antibody
Sign up for CuriRx’s Complimentary Lunch & Learn on November 9 at MassBio!
Join CuriRx for a complimentary lunch & learn about our CuriLytics® platform! CuriLytics®: De-risking CMC characterization by using high-resolution mass spectrometry Date: Tuesday, November 9th, 2021 Time: 12:00-1:00 pm Place: MassBio Hub 700 Technology Square, 4th Floor Cambridge, MA 02139 Reserve your seat now Improving and de-risking the overall drug development path from Phase I clinical trials to approval requires advanced analytical assessment of critical quality attributes. Modern biopharmaceutical drugs, such as recombinant proteins, monoclonal
CuriRx Launches CuriLytics® Platform to Provide CMC Analytical Services to Support Complex Biotherapeutic Development Using High Resolution Mass Spectrometry
WILMINGTON, Mass., Sept. 21, 2021 /PRNewswire/ CuriRx, Inc., a leading contract research, development and manufacturing organization(CRDMO), announced today the launch of their new CuriLytics® platform with High-Resolution Chemistry Manufacturing and Control (CMC) analytical services. Led by CuriRx’s team of industry experts and state-of-the-art high-resolution Orbitrap mass spectrometry instrumentation, the CuriLytics™ platform provides support to developers of complex biotherapeutics. Learn more about CuriLytics™ here. Read the full press release here.
Characterization of Co-Formulated High-Concentration Broadly Neutralizing Anti-HIV-1 Monoclonal Antibodies for Subcutaneous Administration
Introduction Antibodies 2020, 9(3), 36; https://doi.org/10.3390/antib9030036 (registering DOI) Received: 26 June 2020 / Revised: 21 July 2020 / Accepted: 23 July 2020 / Published: 29 July 2020 (This article belongs to the Special Issue Monoclonal Antibody-Directed Therapy) Download PDF Version Authors The paper is authored by Vaneet K. Sharma (1), Bijay Misra (2), Kevin T. McManus (3), Sreenivas Avula (1), Kaliappanadar Nellaiappan (2), Marina Caskey (4), Jill Horowitz (4), Michel C. Nussenzweig (4), Michael S. Seaman (3), Indu Javeri